1. 1669Increased rate of previous stroke in asymptomatic/minimally symptomatic versus symptomatic patients with newly detected atrial fibrillation in western Europe - results from the GLORIA-AF registry. (20th June 2017) Authors: Christow, S.; Seidl, K.; Diener, H-C; Huisman, MV.; Lip, GYH; Rauch-Kroenert, U.; Schuster, S.; Brachmann, J.; Muegge, A.; Schwimmbeck, P-L; Teutsch, C.; Senges, J. Journal: Europace Issue: Volume 19(2017)Supplement 3 Page Start: iii355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Attitudes towards continuous professional development and postgraduate education of Croatian students of physiotherapy. (November 2016) Authors: Sklempe Kokic, I.; Schuster, S.; Brumnic, V.; Crnkovic, I.; Znika, M. Journal: Physiotherapy Issue: Volume 102(2016)Supplement 1 Page Start: e132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS. (12th June 2019) Authors: Bachanova, V.; Westin, J.; Tam, C.; Borchmann, P.; Jaeger, U.; McGuirk, J.; Holte, H.; Waller, E.; Jaglowski, S.; Bishop, M.; Andreadis, C.; Foley, S.R.; Fleury, I.; Teshima, T.; Mielke, S.; Salles, G.; Ho, P.J.; Izutsu, K.; Maziarz, R.; Van Besien, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 308 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Dickinson, M.; Popplewell, L.; Kolstad, A.; Ho, P.J.; Teshima, T.; Dreyling, M.; Schuster, S.; Thieblemont, C.; Ghosh, M.; Riedell, P.; Yateman, N.; Lehnhoff, K.; Lawniczek, T.; Pacaud, L.; Fowler, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EVITA: PHASE I/II STUDY OF EVEROLIMUS PLUS ITACITINIB IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA. (12th June 2019) Authors: Svoboda, J.; Barta, S.; Nasta, S.; Landsburg, D.; Gerson, J.; Ruella, M.; Waite, T.; King, C.; Emanuel, S.A.; Ballard, H.; Schuster, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy. (December 2016) Authors: Roberts, P.; He, S.; Schvartsman, G.; Patil, T.; Sorrentio, J.; Bisi, J.; Hoyer, R.; Schuster, S.; Strum, J.; Heymach, J.; Ferrarotto, R.; Sharpless, N.; Shapiro, G.; Malik, R. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Hepatic and cardiac and iron overload detected by T2* magnetic resonance (MRI) in patients with myelodisplastic syndrome: A cross-sectional study. (January 2019) Authors: Mantovani, L.F.; Santos, F.P.S.; Perini, G.F.; Nascimento, C.M.B.; Silva, L.P.; Wroclawski, C.K.; Esposito, B.P.; Ribeiro, M.S.S.; Velloso, E.D.R.P.; Nomura, C.H.; Kay, F.U.; Baroni, R.H.; Hamerschlak, N.; Schuster, S. Journal: Leukemia research Issue: Volume 76(2019) Page Start: 53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Intravascular ultrasound in patients with acute pulmonary embolism after treatment with intravenous urokinase and high-dose heparin. (January 1997) Authors: Görge, G.; Schuster, S.; Ge, J.; Meyer, J.; Erbel, R. Journal: Heart Issue: Volume 77(1997)Supplement 1 Page Start: 73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL. (12th June 2019) Authors: Jaeger, U.; Tam, C.; Borchmann, P.; McGuirk, J.; Holte, H.; Waller, E.; Jaglowski, S.; Andreadis, C.; Foley, S.R.; Fleury, I.; Westin, J.; Teshima, T.; Mielke, S.; Salles, G.; Ho, P.J.; Izutsu, K.; Schuster, S.; Bachanova, V.; Maziarz, R.; Van Besien, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 505 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. (23rd June 2022) Authors: Dickinson, M.; Martinez-Lopez, J.; Jousseaume, E.; Anjos, C.; Yang, H.; Chai, X.; Wang, T.; Ramos, R.; Lobetti-Bodoni, C.; Schuster, S.; Fowler, N. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1001 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗